标准•方案•指南

从实践提炼共识,以共识指导实践:《儿童呼吸道合胞病毒感染临床诊治中国专家共识(2023年版)》解读

  • 黄丽素 ,
  • 林罗娜 ,
  • 张贤丽
展开
  • 国家儿童健康与疾病临床医学研究中心 浙江大学医学院附属儿童医院感染科(浙江杭州 310003)

收稿日期: 2024-05-23

  网络出版日期: 2024-06-07

From practice to consensus, from consensus to practice: interpretation of Chinese expert consensus on the diagnosis and treatment of respiratory syncytial virus infections in children (2023 edition)

  • Lisu HUANG ,
  • Luona LIN ,
  • Xianli ZHANG
Expand
  • National Clinical Medical Research Center for Child Health and Disease, Infectious Disease Department, Children's Hospital of Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang, China

Received date: 2024-05-23

  Online published: 2024-06-07

摘要

呼吸道合胞病毒(RSV)感染是全球卫生问题,对5岁以下儿童的健康造成了严重的威胁。本文紧扣《儿童呼吸道合胞病毒感染临床诊治中国专家共识(2023年版)》,围绕RSV病原学诊断的窗口期、RSV迟发性重症、RSV支持治疗等关键问题进行深度解读。

本文引用格式

黄丽素 , 林罗娜 , 张贤丽 . 从实践提炼共识,以共识指导实践:《儿童呼吸道合胞病毒感染临床诊治中国专家共识(2023年版)》解读[J]. 临床儿科杂志, 2024 , 42(6) : 553 -557 . DOI: 10.12372/jcp.2024.24e0523

Abstract

Respiratory syncytial virus (RSV) infection is a global health issue that poses a serious threat to the health of children under the age of 5. This article closely follows the “Chinese expert consensus on the clinical diagnosis and treatment of respiratory syncytial virus infection in children (2023 edition)”, and makes an in-depth interpretation of key issues such as the window period for RSV pathogenic diagnosis, late-onset severe disease of RSV, and supportive treatment of RSV.

参考文献

[1] 国家儿童健康与疾病临床医学研究中心, 中华医学会儿科学分会感染学组, 上海市医学会感染病分会, 等. 儿童呼吸道合胞病毒感染临床诊治中国专家共识(2023年版)[J]. 临床儿科杂志, 2024, 42(1): 1-14.
[2] Zhang XL, Zhang X, Hua W, et al. Expert consensus on the diagnosis, treatment, and prevention of respiratory syncytial virus infections in children[J]. World J Pediatr, 2024, 20(1): 11-25.
[3] Meslé MMI, Sinnathamby M, Mook P, et al. Seasonal and inter-seasonal RSV activity in the European Region during the COVID-19 pandemic from autumn 2020 to summer 2022[J]. Influenza Other Respir Viruses, 2023, 17(11): e13219.
[4] Reicherz F, Xu RY, Abu-Raya B, et al. Waning immunity against respiratory syncytial virus during the coronavirus disease 2019 pandemic[J]. J Infect Dis, 2022, 226(12): 2064-2068.
[5] Hamid S, Winn A, Parikh R, et al. Seasonality of respiratory syncytial virus - United States, 2017-2023[J]. MMWR Morb Mortal Wkly Rep, 2023, 72(14): 355-361.
[6] Adams G, Moreno GK, Petros BA, et al. Viral lineages in the 2022 RSV surge in the United States[J]. N Engl J Med, 2023, 388(14): 1335-1337.
[7] 李洋, 李颖, 杜慧, 等. 2020—2023年湖北省某儿童医院呼吸道合胞病毒的临床流行病学特征分析[J]. 中华预防医学杂志, 2024, 58(2): 213-218.
[8] 孙宇, 朱汝南, 王芳, 等. 2023年春季北京地区儿童急性呼吸道感染病原谱分析[J]. 中华儿科杂志, 2024, 62(2): 159-164.
[9] Fretzayas A, Moustaki M. Etiology and clinical features of viral bronchiolitis in infancy[J]. World J Pediatr, 2017, 13(4): 293-299.
[10] Florin TA, Plint AC, Zorc JJ. Viral bronchiolitis[J]. Lancet, 2017, 389(10065): 211-224.
[11] Meissner HC. Viral Bronchiolitis in Children[J]. N Engl J Med, 2016, 374(1): 62-72.
[12] Oakley E, Brys T, Borland M, et al. Medication use in infants admitted with bronchiolitis[J]. Emerg Med Australas, 2018, 30(3): 389-397.
[13] Farley R, Spurling GK, Eriksson L, et al. Antibiotics for bronchiolitis in children under two years of age[J]. Cochrane Database Syst Rev, 2014, 2014(10): CD005189.
[14] Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis[J]. Lancet, 2022, 399(10340): 2047-2064.
[15] Kang JM, Lee J, Kim YK, et al. Pediatric intensive care unit admission due to respiratory syncytial virus: retrospective multicenter study[J]. Pediatr Int, 2019, 61(7): 688-696.
[16] 《中华儿科杂志》编辑委员会, 中华医学会儿科学分会呼吸学组. 毛细支气管炎诊断、治疗与预防专家共识(2014年版)[J]. 中华儿科杂志, 2015, 53(3): 168-171.
[17] Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis[J]. Pediatrics, 2014, 134(5): e1474-e1502.
[18] Alharbi AS, Alqwaiee M, Al-Hindi MY, et al. Bronchiolitis in children: the Saudi initiative of bronchiolitis diagnosis, management, and prevention (SIBRO)[J]. Ann Thorac Med, 2018, 13(3): 127-143.
[19] Dysart K, Miller TL, Wolfson MR, et al. Research in high flow therapy: mechanisms of action[J]. Respir Med, 2009, 103(10): 1400-1405.
[20] Sinha IP, McBride AKS, Smith R, et al. CPAP and high-flow nasal cannula oxygen in bronchiolitis[J]. Chest, 2015, 148(3): 810-823.
[21] Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis[J]. Cochrane Database Syst Rev, 2014, 2014(6): CD001266.
[22] Cai Z, Lin Y, Liang J. Efficacy of salbutamol in the treatment of infants with bronchiolitis: A meta-analysis of 13 studies[J]. Medicine (Baltimore), 2020, 99(4): e18657.
[23] Midulla F, Nenna R, Scagnolari C, et al. How respiratory syncytial virus genotypes influence the clinical course in infants hospitalized for bronchiolitis[J]. J Infect Dis, 2019, 219(4): 526-534.
[24] Lin J, Zhang Y, Song A, et al. Exploring the appropriate dose of nebulized hypertonic saline for bronchiolitis: a dose-response meta-analysis[J]. J Investig Med, 2022, 70(1): 46-54.
[25] Hsieh CW, Chen C, Su HC, et al. Exploring the efficacy of using hypertonic saline for nebulizing treatment in children with bronchiolitis: a meta-analysis of randomized controlled trials[J]. BMC Pediatr, 2020, 20(1): 434.
[26] Mandelberg A, Amirav I. Hypertonic saline or high volume normal saline for viral bronchiolitis: mechanisms and rationale[J]. Pediatr Pulmonol, 2010, 45(1): 36-40.
[27] Wang X, Li Y, Shi T, et al. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data[J]. Lancet, 2024, 403(10433): 1241-1253.
[28] Wu N, Zhang J, Shen Y, et al. A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections[J]. Mol Ther, 2024, 32(4): 1033-1047.
文章导航

/